Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Main Content

Mild Cognitive Impairment in Parkinson Disease (PD-MCI) Study Group

Gert J. Geurtsen Alex Tröster Jennifer G. Goldman
Chair: Gert J. Geurtsen Vice Chair: Alexander I. Tröster Vice Chair: Jennifer G. Goldman

 

MDS Staff Liaison: Finoula Harrington​​​​​​​

Open AllClose All
  Steering Committee

Irene Litvan PhD, Ben A. Schmand PhD, Alexander I. Trőster PhD, Jennifer G. Goldman PhD and David J. Burn PhD.

  PhD Students

J. Hoogland MD Msc

  Post-doc

J.A. Boel, PhD

  Members

Members:
USA
•    Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush University Medical Center, Chicago, IL
(Bryan Bernard PhD and Glenn Stebbins PhD); 
•    Shirley Ryan AbilityLab and Northwestern University, Departments of Physical Medicine and Rehabilitation and Neurology, Chicago, IL (Jennifer G. Goldman MD MS)
•    Department of Clinical Neuropsychology and Center for Neuromodulation, Phoenix, AZ (Alexander I. Troster PhD);
•    Department of Neurosciences University of California San Diego, Parkinson and Other Movement Disorder Center, San Diego, California (J. Vincent Filoteo PhD and Irene Litvan PhD)
•    Departments of Psychiatry and Neurology and Parkinson’s Disease and Mental Illness Research, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA (Daniel Weintraub PhD);
•    Arizona Study of Aging and Neurodegenerative Disorders, Mayo Clinic Arizona, Scottsdale, AZ and Banner Sun Health Research Institute, Sun City, AZ (Charles H. Adler, PhD, John N. Caviness, MD and Christine Belden, PhD);
•    Veterans Affairs Puget Sound Health Care System and Department of Neurology, University of Washington School of Medicine, Seattle, WA (Cyrus P. Zabetian MD, MSc, and Brenna A. Cholerton PhD); 
•    Department of Neurology, Hershey Medical Center (Xuemei Huang PhD and Paul J. Eslinger PhD);
•    Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic (James B. Leverenz, MD);

Canada
•    Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson’s disease, Toronto Western Hospital, University of Toronto (Connie Marras MD, PhD and Sarah Duff-Canning PhD sarah.duffcanning@uhnresearch.ca);
•    The Centre for Applied Neurogenetics, University of British Columbia (Matt Farrer PhD),

New Zealand
•    New Zealand Brain Research Institute, Brain Research New Zealand - Rangahau Roro Aotearoa, Christchurch, (John C. Dalrymple-Alford PhD and Tim J. Anderson FRACP and Daniel J Myall PhD);

Australia
•    Brain & Mind Centre, University of Sydney (Sharon L. Naismith PhD, Simon JG Lewis MD) and Neuroscience Research Australia, University of New South Wales (Glenda M. Halliday PhD);

Asia
•    Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan (Ruey-Meei Wu, MD, PhD);
•    Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan (R.L. Yu, PhD);

UK
•    John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK (Caroline H. Williams-Gray MRCP PhD, David P. Breen MRCP PhD and Roger A. Barker MRCP PhD);
•    Faculty of Medical Sciences, Clinical Ageing Research Unit, Translational and Clinical Research Institute Newcastle University, Newcastle upon Tyne, UK (Alison J. Yarnall MRCP PhD and David J. Burn PhD, Rachael A Lawson, PhD);
•    

Germany
•    Paracelsus-Elena-Klinik, Kassel, Germany, and University Medical Center Goettingen, Department of Neurosurgery and Institute of Neuropathology, Goettingen, Germany (Brit Mollenhauer MD) Paracelsus-Elena-Klinik, Kassel, Germany, and University Medical Center Goettingen, Department of Neurosurgery, Goettingen, Germany, (Claudia Trenkwalder MD);

Spain
•    Movement Disorders Unit, Neurology Department, Hospital and Institute of Biomedical Research Sant Pau, 'CIBERNED', Barcelona, Spain (Jaime Kulisevsky MD PhD and Javier Pagonabarraga MD PhD) and 'Universitat Oberta de Catalunya'  (Jaime Kulisevsky MD PhD);
•    Department of Neurology, Hospital Donostia, San Sebastian and Ikerbasque, Basque Foundation for Science, Bilbao, Spain (Carmen Gasca-Salas MD, PhD)Clinica Universidad de Navarra Spain (Maria C. Rodriguez-Oroz MD, PhD)
•    Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine, IDIBAPS, University of Barcelona, Spain (Carme Junque PhD and Barbara Segura PhD);

Italy 
•    Neurogenerative disease centre, University of Salerno, Salerno, Italy (Paolo Barone PhD) and Department of Psychology, Second University of Naples, Italy (Gabriella Santangelo PhD);
•    Department of Surgery, Medical, Molecular, and Critical Area Pathology, University School of Medicine, Pisa (Davide M Cammisuli PhD);
•    Parkinson Unit, Fondazione Ospedale San Camillo IRCCS, Venice (Roberta Biundo PhD, Angelo Antonini PhD and Luca Weis PhD);

Norway
•    The Norwegian Centre for Movement Disorders, Department of Neurology, and Memory Clinic, Stavanger University Hospital, Stavanger, Norway (Kenn Freddy Pedersen PhD and Guido Alves PhD).

The Netherlands
•    Department of Neurology (Rob MA de Bie PhD) and Department of Medical Psychology (Ben A. Schmand PhD and Gert J Geurtsen PhD), Academic Medical Center Amsterdam, The Netherlands;
•    Department of Medical Psychology, section Medical Neuropsychology, VU University Medical Center, Amsterdam, The Netherlands (Martin Klein PhD).
New members:
•    Naroa Ibarretxe Bilbao, University of Deusto, Bilbao, Spain
•    Rimona Weil Wellcome Trust, Dementia Research Centre, University College London, UK.
•    Paolo Amami, Humanitas Research Hospital, Milan, Italy
•    Elena Cecilia Rosca, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

Goals:

  1. Validation of the MDS PD-MCI criteria
  • comparison of the two levels of criteria (abbreviated assessment {I} versus comprehensive assessment {II}) in their ability to detect PD-MCI and predict conversion to dementia
  • applicability of the criteria
  1. Generating epidemiologic data by
  • defining the prevalence of PD-MCI
  1. Determine relationship PD-MCI, mood and Quality of Life
  • analyzing mood and Quality of Life in no-PD-MCI, PD-MCI and PDD groups.

DESCRIPTION OF CURRENT ACTIVITIES AND FUTURE PLANS:

This Study Group was recognized by the MDS at the end of 2012. The recently proposed MDS diagnostic criteria for MCI in PD (PD-MCI) need to be validated. This Study Group will validate these criteria by:

  1. combining and analyzing comprehensive neuropsychological cross-sectional data-bases and longitudinal data-bases (follow up at least one year) {≥ 3,500 PD patients and ≥ 1,400 controls};
  2. applying the MDS PD-MCI criteria to validate Level I in 3,000 patients and Level II in 1,000 patients;
  3. investigating the predictive value of the PD-MCI criteria;
  4. revise the MDS PD-MCI criteria if necessary

Goals:

  1. Validation of the MDS PD-MCI criteria
  • comparison of the two levels of criteria (abbreviated assessment {I} versus comprehensive assessment {II}) in their ability to predict conversion to dementia
  • comparison PD-MCI based on screeners to the level I and level II PD-MCI in their ability to predict conversion to dementia
  • applicability of the criteria
  1. Determine relationship of PD-MCI, mood and Quality of Life
  • analyzing mood and Quality of Life in non-PD-MCI, PD-MCI and PDD groups.

 

Additional Information: 23 international sites have PD cohorts that will be combined. These cohorts include ≥ 3,500 PD patients and ≥ 1,400 controls. Two PhD students started in October 2013 and we are currently finalizing the validation project. An overview of the research plans is published in the Journal of Parkinson’s Disease and a validation papers have been published.

Undertaken activities:

  • Bi-monthly steering committee meetings;
  • Study Group meetings at MDS congress (Sydney; Stockholm, San Diego, Berlin Vancouver, HongKong and Nice);
  • Manuscript published in Journal of Parkinson’s Disease:

Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Trőster AI, Burn DJ, Litvan  I. Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. J Parkinson’s Dis. 2014 (4): 131-137;

  • Presented preliminary results at NMPD in Nice and British-Dutch Neuropsychological Association, at MDS meeting in San Diego and NMPD meeting in Ljubljana, at MDS meeting in Berlin and Vancouver;
  • Paper on level II PD-MCI criteria published: Hoogland J, Boel JA, Bie RMA de, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Mild cognitive impairment as a risk factor for Parkinson’s disease dementia. Movement Disorders 2017; 32(7):1056-1065;
  • Performed additional project on PD-MCI PDD and DNA/genetic markers in cooperation with Matt Farrer; Paper published: Guella I, Evans DM, Szu-Tu C, Nosova E, Bortnick SF, Goldman JG, Dalrymple-Alford J, Geurtsen GJ, Litvan I, Ross OA, Middleton LT, Parkkinen L,  Farrer MJ. α-synuclein genetic variability: a biomarker for dementia in Parkinson’s disease. Annals of Neurology 2016; 79(6):991-999;Performed an additional project on in cooperation with Daniel Weintraub: Parkinson Neuropsychological Battery: Which tests best differentiate PD from controls; Paper published: Hoogland J, Wanrooij LL van, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, Bie RMA de, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ #, and Daniel Weintraub MD #, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Detecting mild cognitive deficits in Parkinson disease: comparison of neuropsychological tests. Movement Disorders. 2018; 33(11): 1750-1759.
  • Prepared an additional project on PD-MCI dementia risk score in cooperation with John Dalrymple-Alford, Tim Anderson and Matt Farrer. Looking for funding;
  • Paper validation of level I PD-MCI published; Hoogland J, Boel JA, Bie RMA de, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Risk of Parkinson’s disease dementia related to level I MDS PD-MCI. Movement Disorders 2019; 34(3): 430-435.
  • Currently preparing analysis of predictive value of screeners for dementia compared to level I and II PD-MCI.
     

Grants:

  • Michael J. Fox Foundation;
  • Parkinson Vereniging (Dutch Parkinsons Disease Association);
  • Additional grant concerning Michael J. Fox Foundation (Parkinson Neuropsychological Battery);
  • Additional grant concerning Michael J. Fox Foundation (α-synuclein genetic variability);
  • Additional grant concerning Michael J. Fox Foundation (Comparison screeners versus Level I and Level II).
     

Activities planned:

  • Papers on level I and Level II PD-MCI criteria have been published. Other manuscript is being prepared now.
     

Spin off:

  • Finished additional project on PD-MCI/PDD and DNA/genetic markers in cooperation with Matt Farrer; paper  Guella et al. α-synuclein genetic variability: a biomarker for dementia in Parkinson’s disease. Annals of Neurology 2016; 79(6):991-999;
  • Finished additional project on in cooperation with Daniel Weintraub: Parkinson Neuropsychological Battery: Which tests best differentiate PD from controls; Paper published.
  • In preparation project on enhanced dementia risk score based on neuropsychological tests and genetics;
     

Papers published:

  • Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Trőster AI, Burn DJ, Litvan  I. Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. J Parkinson’s Dis. 2014 (4): 131-137.
  • Guella I, Evans DM, Szu-Tu C, Nosova E, Bortnick SF, Goldman JG, Dalrymple-Alford J, Geurtsen GJ, Litvan I, Ross OA, Middleton LT, Parkkinen L, Farrer MJ. α-synuclein genetic variability: a biomarker for dementia in Parkinson’s disease. Annals of Neurology 2016; 79(6):991-999;
  • Hoogland J, Boel JA, Bie RMA de, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Mild cognitive impairment as a risk factor for Parkinson’s disease dementia. Movement Disorders 2017; 32(7):1056-1065.
  • Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu R-M, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Detecting mild cognitive deficits in Parkinson disease: comparison of neuropsychological tests. Movement Disorders. 2018 33;11: 1750-1759.
  • Hoogland J, Boel JA, Bie RMA de, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Risk of Parkinson’s disease dementia related to level I MDS PD-MCI. Movement Disorders 2019: 34 (3); 430-435.

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice